NASDAQ:MGNX

Macrogenics Stock Insider Trading

Healthcare > Biotechnology

Buy MGNX

*Your capital is at risk

$4.69

+0.110 (+2.40%)

At Close: Jun 23, 2026

MacroGenics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 96.57. In total, the insiders bought 2.21M and sold 56.02K MGNX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	96.57
● Buy	2.21M shares
● Sell	56.02K shares
84% Buy Activity Moderate Negative Correlation
Buy Signal High Confidence Feb 12, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 96.57. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (84% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 18, 2026 Buy	Restricted Stock Unit M-Exempt	Jackson Scott Thomas Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Common Stock M-Exempt	Jackson Scott Thomas Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Restricted Stock Unit M-Exempt	O'brien Federica F. Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Common Stock M-Exempt	O'brien Federica F. Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Common Stock M-Exempt	Ferrante Karen Jean Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Common Stock M-Exempt	Siegel Jay Philip Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Restricted Stock Unit M-Exempt	Siegel Jay Philip Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Common Stock M-Exempt	Liu Margaret Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Common Stock M-Exempt	Hurwitz Edward Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Restricted Stock Unit M-Exempt	Ferrante Karen Jean Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Common Stock M-Exempt	Stump David C Director	Director	3 750 Value: $16.3K
Feb 15, 2026 Buy	Restricted Stock Unit M-Exempt	Koenig Scott Director	Director	21 165 Value: $99.3K
Feb 15, 2026 Buy	Common Stock M-Exempt	Koenig Scott Director	Director	21 165 Value: $99.3K
Feb 15, 2026 Buy	Restricted Stock Unit M-Exempt	Risser Eric Blasius President And CEO	CEO / President	16 665 Value: $78.2K
Feb 15, 2026 Sell	Common Stock F-InKind	Risser Eric Blasius President And CEO	CEO / President	6 433 Value: $11.0K
Feb 15, 2026 Buy	Common Stock M-Exempt	Risser Eric Blasius President And CEO	CEO / President	16 665 Value: $78.2K
Feb 15, 2026 Buy	Restricted Stock Unit M-Exempt	Spitznagel Thomas Sr Vp, Technical Ops	Officer	13 332 Value: $62.5K
Feb 15, 2026 Sell	Common Stock F-InKind	Spitznagel Thomas Sr Vp, Technical Ops	Officer	5 520 Value: $9K
Feb 15, 2026 Buy	Common Stock M-Exempt	Spitznagel Thomas Sr Vp, Technical Ops	Officer	13 332 Value: $62.5K
Feb 15, 2026 Buy	Restricted Stock Unit M-Exempt	Peters Jeffrey Stuart Senior Vp, GC, And Secretary	Officer	13 332 Value: $62.5K
Feb 15, 2026 Sell	Common Stock F-InKind	Peters Jeffrey Stuart Senior Vp, GC, And Secretary	Officer	5 147 Value: $9K
Feb 15, 2026 Buy	Common Stock M-Exempt	Karrels James SVP And CFO	C-Suite Officer	14 999 Value: $70.3K
Feb 15, 2026 Sell	Common Stock F-InKind	Smith Beth Ann Vp, Controller & Treasurer	Officer	423 Value: $723
Feb 15, 2026 Buy	Common Stock M-Exempt	Smith Beth Ann Vp, Controller & Treasurer	Officer	1 095 Value: $5K
Feb 15, 2026 Buy	Restricted Stock Unit M-Exempt	Bonvini Ezio Sr Vp, Research & Cso	Officer	16 665 Value: $78.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MACROGENICS

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The...

Read Full Profile Here